Healthpeak Properties: Sell-Off Has Gone Too Far, I'm Buying This High-Yield Dividend REIT (Upgrade)
Healthpeak Properties is upgraded to Strong Buy, driven by resilient financials, high yield, and recovery potential despite lab segment weakness. DOC offers a sustainable 7.3% annualized monthly dividend yield with a conservative ~72% AFFO payout ratio, supporting both buybacks and acquisitions while their asset recycling continues. Management anticipates a pivotal 2026, with portfolio rebalancing, $1 billion in asset sales, recapitalizations, and loan repayments, with early signs of a lab segment inflection point.
2 REITs That Look Attractive in a Stable Rate Environment
The Trump administration may have unintentionally thrown a bone to the real estate investment trust (REIT) industry. President Trump's nomination of Kevin Warsh to be the next chair of the Federal Reserve provides more clarity, and more importantly, predictability to the course of rate cuts in 2026.
Healthpeak Properties, Inc. (DOC) Q4 2025 Earnings Call Transcript
Healthpeak Properties, Inc. (DOC) Q4 2025 Earnings Call Transcript
Healthpeak's Pivot: A Masterclass In Value Destruction (Rating Downgrade)
Healthpeak Properties (DOC) is rated HOLD due to poor capital allocation, underperformance, and execution risk despite an attractive, well-covered 7% dividend yield. Recent strategic pivot includes spinning off senior housing assets into Janus Living, but external management and dual-CEO structure introduce significant execution risk. DOC trades at a 15–20% discount to NAV, failed to achieve targeted FFO growth and stability, and underperformed VNQ by nearly 60% since 2019.
Healthpeak Q4 FFO Beats Estimates, Same-Store NOI Rises Y/Y
DOC tops Q4 FFO and revenue estimates, driven by same-store NOI growth, while outlining portfolio reshaping and new strategic initiatives.
Healthpeak (DOC) Beats Q4 FFO and Revenue Estimates
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.47 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to FFO of $0.46 per share a year ago.
Healthpeak Properties Stock Up 13.5% in a Month: Will the Trend Last?
DOC shares rise 13.5% in a month as lab demand, senior care growth and $925M in deals highlight its capital strategy.
Healthpeak Properties: San Francisco Is Recovering - But Monetization, Not Exposure, Determines The Right REIT
Healthpeak Properties has concentrated exposure to South San Francisco life-science assets, allowing it to benefit from the region's innovation-led recovery without relying on downtown office demand. DOC's portfolio is diversified nationally, with 23% of NOI coming from San Francisco while Outpatient Medical assets provide the majority of stable cash flow. The portfolio has a 7.3-year average lease term, with longer Outpatient Medical leases providing stability and shorter Lab leases allowing faster adjustment as leasing conditions improve.
Healthpeak Monetizes Senior Housing Assets Through Janus Living IPO
DOC aims to unlock value in its senior housing platform by spinning out Janus Living via an IPO while retaining control and recurring management income.
Healthpeak Properties: Weighing Lab Pressure Against Long-Term Fundamentals
Healthpeak Properties remains a contrarian, long-term opportunity, with management focused on capital allocation, a covered dividend, and technology-driven efficiencies. DOC plans to recycle $1B+ from outpatient medical asset sales into higher-return lab assets, targeting double-digit unlevered IRRs despite near-term sector headwinds. Lab and outpatient segments show improving leasing pipelines, with occupancy expected to bottom in the high 70s before recovery, while CCRC delivers strong NOI growth.
Here's Why Healthpeak (DOC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 New Year's Resolution Stocks That Could Turn Around in 2026
At the start of the new year, investors seeking a fresh approach might consider stocks that are positioned for a reset. Companies trading at or near their lowest level for 2025 could be primed for gains in the new year if conditions are right.
